Pfizer planning Phase III for DMD gene therapy, close on Sarepta's heels

Undeterred by two patient hospitalizations revealed in Phase Ib data Friday for its DMD gene therapy, Pfizer is moving forward with plans for a Phase III trial start in 1H20, setting up a tight race to the finish line between it and Sarepta.

Pfizer Inc. (NYSE:PFE) said at the Parent Project

Read the full 501 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE